LLYLLYHealthcare · Drug Manufacturers - General

LLY Stock Forecast: Eli Lilly & Co. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1,347
−0.30% on the day

The 31 Wall Street analysts covering Eli Lilly & Co. hold a median 12-month price target of $1,573 — +16.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.2T
Ticker Nerd rank
92/ 100
Median analyst target
$1,573
Analysts covering
31
Revenue$23.0B+47.7% y/y
Operating income$12.5B
Net income$7.1B
Free cash flow$4.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.7%
1M
+5.1%
YTD
+26.1%
1Y
+29.9%
From 52W high
−6.7%
From 52W low
+58.9%
$848
$1,444
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Eli Lilly & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
92/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Volatility
97
Momentum
96
Value
96
Revisions
92
Growth
80
Issuance
45
Accruals
19

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LLY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LLY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$800$1,000$1,200$1,400$1,600$1,800Jan 26Apr 26Jul 26Oct 26LLYHigh $1,700Median $1,573Low $940

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says31 analysts
25
Buy
4
Hold
2
Sell
$940
Low
$1,573
Median
$1,700
High

The green dot is the last close — the median target sits +16.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 16 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026RBC CapitalReiteratesOutperform$1,600
16 Nov 2026BarclaysMaintainsOverweight$1,400 → $1,550
9 Nov 2026JefferiesMaintainsBuy$1,610 → $1,700
2 Nov 2026Cantor FitzgeraldMaintainsOverweight$1,440 → $1,600
31 Oct 2026UBSMaintainsBuy—
30 Oct 2026Argus ResearchMaintainsBuy$1,300 → $1,550
30 Oct 2026CitigroupMaintainsBuy$1,600 → $1,650
30 Oct 2026JP MorganMaintainsOverweight$1,500 → $1,650
30 Oct 2026Morgan StanleyMaintainsOverweight$1,430 → $1,596
30 Oct 2026RBC CapitalMaintainsOutperform$1,500 → $1,600
30 Oct 2026ScotiabankMaintainsSector Outperform$1,300 → $1,605
30 Oct 2026Truist SecuritiesReiteratesBuy$1,376 → $1,612
30 Oct 2026UBSMaintainsBuy$1,425 → $1,625
30 Oct 2026Wells FargoMaintainsOverweight$1,330 → $1,500
21 Oct 2026Leerink PartnersMaintainsOutperform$1,309 → $1,316
12 Oct 2026RBC CapitalReiteratesOutperform$1,500
8 Oct 2026Cantor FitzgeraldMaintainsOverweight$1,410 → $1,440
7 Oct 2026Morgan StanleyMaintainsOverweight$1,419 → $1,430
28 Sept 2026JP MorganMaintainsOverweight$1,400 → $1,500
22 Sept 2026TD CowenReiteratesBuy$1,250

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LLY.

Market Radar

This page is one stock. Monday covers all of them.

LLY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LLY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Eli Lilly & Co. returned +29.9% against +6.9% for the S&P 500, dividends included.

LLY vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26LLYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LLY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−3.4%
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
43.9×

Cheaper than 19% of US stocks

Price / sales
13.9×

Cheaper than 10% of US stocks

Price / book
30.0×

Cheaper than 2% of US stocks

EV / EBITDA
26.8×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
15.5%

Higher than 55% of US stocks

Gross margin
85.8%

Higher than 94% of US stocks

Operating margin
51.3%

Higher than 97% of US stocks

Net margin
31.9%

Higher than 90% of US stocks

Returns & dividend
Return on equity
86.0%

Higher than 96% of US stocks

Return on assets
21.1%

Higher than 99% of US stocks

Dividend yield
0.5%

Higher than 9% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eli Lilly & Co. has a market value of $1.2T and an enterprise value of $1.2T.

  • Revenue in the twelve months to 30 June 2026: $79.7B. The latest quarter grew 47.7% year on year.

  • Net income over the same four quarters: $26.7B, a 33.5% net margin.

  • Diluted earnings per share, trailing twelve months: $29.80.

  • Free cash flow in the twelve months to 30 June 2026: $13.6B.

  • Eli Lilly & Co. spent $6.2B on share buybacks and $5.8B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 891.5M.

  • Trailing P/E: 43.9×; forward P/E: 26.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.51%, paying out 22% of earnings.

  • Eli Lilly & Co. employs 50,000 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LLY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
LLYEli Lilly & Co.$1.2T92
JNJJohnson & Johnson$651.8B86
ABBVAbbVie, Inc.$505.7B90
MRKMerck & Co., Inc.$331.9B86
AMGNAmgen, Inc.$234.8B95
GILDGilead Sciences, Inc.$206.6B89
PFEPfizer Inc.$155.8B91

Take a look at LLY’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Eli Lilly & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LLY

What is the LLY stock price forecast for 2026-2027?

The 31 Wall Street analysts covering Eli Lilly & Co. have a median 12-month price target of $1,573, with estimates ranging from $940 to $1,700. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LLY stock a buy right now?

Of the 31 analysts covering Eli Lilly & Co., 25 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Eli Lilly & Co. 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LLY?

As at 21 Nov 2026, Eli Lilly & Co. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will LLY stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +16.8% from the last close, and Ticker Nerd's factor model ranks Eli Lilly & Co. 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LLY stock forecast for 2030?

No analyst covering Eli Lilly & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LLY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $940 to $1,700 over the next 12 months.

How has LLY stock performed over the past year?

Eli Lilly & Co. returned +29.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eli Lilly & Co. do?

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide.

Company

About Eli Lilly & Co.

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.

CEO Mr. David A. Ricks · 50,000 employees · United States · https://www.lilly.com